Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Estimated reading time for CME/CPD: 1 min

Clozapine, suicide prevention and risk perception in psychiatry

AI Summary
  • Clozapine is the most effective treatment for treatment-resistant schizophrenia and consistently linked with reduced suicidal behaviour.
  • Use remains markedly limited despite advances in pharmacovigilance, haematological monitoring and individualised prescribing strategies.
  • Psychiatry often emphasises treatment-attributable mortality while underplaying severe mental illness lethality, particularly suicide, with clozapine exposing this conceptual tension.
Summarise with AI (MRCPsych/FRANZCP)

BJPsych Bull. 2026 Oct 19:1-3. doi: 10.1192/bjb.2026.10317. Online ahead of print.

ABSTRACT

Clozapine remains the most effective treatment for treatment-resistant schizophrenia and one of the few psychiatric medications consistently associated with reduced suicidal behaviour. Nevertheless, its use remains markedly limited despite advances in pharmacovigilance, haematological monitoring and individualised prescribing strategies. This editorial examines whether psychiatry may continue to evaluate clozapine through historically inherited models of risk perception that emphasise treatment-attributable mortality while insufficiently incorporating the lethality of severe mental illness itself, particularly suicide. Clozapine therefore represents not only a psychopharmacological treatment, but also a revealing case study in how psychiatry conceptualises competing forms of mortality.

PMID:42894411 | DOI:10.1192/bjb.2026.10317

Document this CPD

Share Evidence Blueprint

QR Code

Save to Google Notes

Search Google Scholar

Save as PDF

⭐ My Revision List

close chatgpt icon
ChatGPT

Enter your request.

← →
RAISR4D CME/CPD Evidence Nodes
Swipe to navigate RAISR4D CME/CPD evidence nodes.
CME/CPD